InflaRx N.V. (IFRX) Form 6-K — Jun 30, 2026
The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended revoking the marketing authorization for Tavneos in the European Union on June 26, 2026, removing the only approved targeted therapy for ANCA-associated vasculitis (AAV) from the EU market. InflaRx is now assessing the feasibility of broadening its development and registrational strategy for AAV in Europe in response to this regulatory action.
Key figures
- Izicopan c5a blockade
- ≥90%
- Izicopan single dose range
- 3 mg to 240 mg
- Izicopan multiple dose range
- 30 mg once per day to 90 mg twice per day
- Vilobelimab 28day mortality reduction
- 23.9%
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.